Institute for Clinical Immunology and Cell Therapeutics

Professor Fricke elected GC‑I³ spokesperson

27.10.2026 -  

Prof. Dr. med. habil. Stephan Fricke, Director of our Institute for Clinical Immunology and Cell Therapeutics (IKIZ), was unanimously elected spokesperson of the Health Campus Immunology, Infectiology and Inflammation (GC-I³) on 10 September 2026. He combines clinical expertise in immunology, haematology and oncology with the development of cell and gene therapies and their translation into clinical practice.

Professor Fricke has held the W3 Professorship in Clinical Immunology and Cell Therapeutics at University Medicine Magdeburg since October 2025. Previously, he served as Executive Senior Physician at Chemnitz Hospital. With certification as a specialist immunologist from the German Society for Immunology and an additional medical qualification in immunology, he brings together the treatment of cancer and immune disorders with applied research. He also serves as Director of Clinical Translation at the Fraunhofer Institute for Cell Therapy and Immunology IZI, where he has worked since 2006.

A key focus of his work is translating experimental manufacturing processes into GMP-compliant procedures for advanced therapy medicinal products (ATMPs), including CAR T-cell therapeutics. This work addresses a critical step between laboratory development and clinical investigation. Further research aims include developing cellular therapies for autoimmune diseases and reducing severe immune complications following cell transplantation.

This combination of patient care, immunological research and pharmaceutical process development shapes the expertise he brings to his role as spokesperson. The GC-I³ provides an interdisciplinary framework for connecting findings on immune regulation, infection and inflammation with clinical research questions.

We warmly congratulate Professor Fricke on his election and wish him every success in his new role.

Last Modification: 02.11.2026 - Contact Person:

Sie können eine Nachricht versenden an: Webmaster
Sicherheitsabfrage:
Captcha
 
Lösung: